Apo A-I is a protein that plays a role in the metabolism of lipids and is one of the main components attached to HDL, commonly referred to as the “good cholesterol”. HDL plays a very important role in removing excess cholesterol from cells and takes it to the liver for recycling or disposal.
Levels of apo A-I is directly proportional to HDL levels in the blood, and deficiencies in apo A-I correlate with an increased risk of developing CVD.
Like Apo-lipoprotein A1, Apo B is also a protein that is involved in the metabolism of lipids and is the main protein constituent of lipoproteins such as very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL, the “bad cholesterol”). Concentrations of apo B is directly proportional to LDL-C. Doctors usually order both an apo A-I (associated with high-density lipoprotein (HDL), the “good” cholesterol) and an apo B to determine an apo B/apo A-I ratio. This ratio is used as an alternative to a total cholesterol/HDL ratio to evaluate risk for developing CVD.
Apo B levels may be ordered to monitor the effectiveness of lipid treatment as an alternative to non-HDL-C (non-HDL-C is the total cholesterol concentration minus the amount of HDL).
Global & National Quality Accreditations – CAP (USA) and NABL , Govt. of India.
Guaranteed error free diagnosis.
Bar Coded and automated process. No room for manual errors.
Specific normal range for Indian population built from 33 years of experience.
Sample collection from home/office.
Metropolis: Experience + Expertise
Over the past 3 decades we have earned the respect of doctors and patients. Today we conduct over 30 million tests annually with accuracy each year. Our repertoire extends over 4500 tests and over 100 different technologies. Our customer care is available round the clock for any queries that you may have.
Save tax on the Preventive health check-ups up to Rs. 5000, under section 80D of Income Tax Act, 1961
We are Metropolis - Your Pathology Specialist
Metropolis is one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan). With operations across India, Africa, South Asia and Middle East.
Our globally accredited clinical laboratories deliver millions of accurate and timely test results every year. We offer a comprehensive range of clinical laboratory tests and profiles which are used in prediction, early detection, diagnostic screening, confirmation and monitoring of diseases.
Delivering diagnostic services since 1980
Network of 100+ clinical labs & 1100+ patient touch points
Qualified team of phlebotomists for Home collection services
Certified NABL and CAP accredited labs
Wide range of 4000+ tests & profiles
Convenience of home collection service
Metropolis Healthcare Limited is proposing subject to applicable statutory or regulatory requirements, receipt of requisite approvals, market conditions and other considerations to undertake an initial public offering of its equity shares and has filed a draft red herring prospectus dated September 27, 2018 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of the SEBI at www.sebi.gov.in, BSE Limited at www.bseindia.com, National Stock Exchange of India Limited at www.nseindia.com and the websites of Book Running Lead Managers at www.jmfl.com, www.credit-suisse.com, www.investmentbank.kotak.com, www.hdfcbank.com and www.goldmansachs.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to same, please refer to the DRHP including the section “Risk Factors” of the DRHP. Potential investors should not rely on the DRHP filed with the SEBI for making any investment decision.